Search

Your search keyword '"Meer, Peter"' showing total 215 results
Start Over Author "Meer, Peter" Publisher wiley
215 results on '"Meer, Peter"'

2. Contemporary guideline‐directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE‐HF study

Author

Malgie, Jishnu, primary, Wilde, Mariëlle I., additional, Clephas, Pascal R.D., additional, Emans, Mireille E., additional, Koudstaal, Stefan, additional, Schaap, Jeroen, additional, Mosterd, Arend, additional, van Ramshorst, Jan, additional, Wardeh, Alexander J., additional, van Wijk, Sandra, additional, van den Heuvel, Mieke, additional, Wierda, Eric, additional, Borleffs, C. Jan Willem, additional, Saraber, Colette, additional, Beeres, Saskia L.M.A., additional, van Kimmenade, Roland, additional, Jansen Klomp, Wouter, additional, Denham, Robert, additional, da Fonseca, Carlos A., additional, Klip, IJsbrand T., additional, Manintveld, Olivier C., additional, van der Boon, Robert M.A., additional, van Ofwegen, Clara E.E., additional, Yilmaz, Ayten, additional, Pisters, Ron, additional, Linssen, Gerard C.M., additional, Faber, Nikola, additional, van Heerebeek, Loek, additional, van de Swaluw, Julio E.C., additional, Bouhuijzen, Lex J., additional, Post, Marco C., additional, Kuijper, Aaf F.M., additional, Wu, Ka wai, additional, van Beek, Eugène A., additional, Hesselink, Tim, additional, Kleijn, Lennaert, additional, Kurvers, Maurice J.M., additional, Tio, René A., additional, Langerveld, Jorina, additional, van Dalen, Bas M., additional, van Eck, J.W. Martijn, additional, Handoko, M. Louis, additional, Hermans, Walter R.M., additional, Koornstra‐Wortel, Hetty J.J., additional, Szymanski, Mariusz K., additional, Rooker, Dennis, additional, Tandjung, Kenneth, additional, Eijsbouts, Sabine C.M., additional, Asselbergs, Folkert W., additional, van der Meer, Peter, additional, Brunner‐La Rocca, Hans‐Peter, additional, de Boer, Rudolf A., additional, and Brugts, Jasper J., additional

Published
2024
Full Text
View/download PDF

4. Prevalence of wild‐type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo‐VIP‐HF study

Author

Tubben, Alwin, primary, Tingen, Hendrea S.A., additional, Prakken, Niek H.J., additional, van Empel, Vanessa P.M., additional, Gorter, Thomas M., additional, Meems, Laura M.G., additional, Manintveld, Olivier C., additional, Rienstra, Michiel, additional, Tieleman, Robert G., additional, Glaudemans, Andor W.J.M., additional, van Veldhuisen, Dirk J., additional, Slart, Riemer H.J.A., additional, Nienhuis, Hans L.A., additional, and van der Meer, Peter, additional

Published
2024
Full Text
View/download PDF

5. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE‐HF

Author

Clephas, Pascal R. D., primary, Malgie, Jishnu, additional, Schaap, Jeroen, additional, Koudstaal, Stefan, additional, Emans, Mireille, additional, Linssen, Gerard C. M., additional, de Boer, Grytsje A., additional, van Heerebeek, Loek, additional, Borleffs, C. Jan Willem, additional, Manintveld, Olivier C., additional, van Empel, Vanessa, additional, van Wijk, Sandra, additional, van den Heuvel, Mieke, additional, da Fonseca, Carlos, additional, Damman, Kevin, additional, van Ramshorst, Jan, additional, van Kimmenade, Roland, additional, van de Ven, Arjen R. T., additional, Tio, René A., additional, van Veghel, Dennis, additional, Asselbergs, Folkert W., additional, de Boer, Rudolf A., additional, van der Meer, Peter, additional, Greene, Stephen J., additional, Brunner‐La Rocca, Hans‐Peter, additional, and Brugts, Jasper J., additional

Published
2023
Full Text
View/download PDF

6. Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial

Author

Schou, Morten, primary, Claggett, Brian, additional, Miao, Zi Michael, additional, Fernandez, Alberto, additional, Filippatos, Gerasimos, additional, Granger, Christopher, additional, Jering, Karola, additional, Maggioni, Aldo P., additional, McCausland, Finnian, additional, Villota, Julio Nuñez, additional, Rouleau, Jean‐Lucien, additional, Mody, Freny Vaghaiwalla, additional, van der Meer, Peter, additional, Vinereanu, Dragos, additional, McGrath, Martina, additional, Zhou, Yinong, additional, Mann, Douglas L., additional, Solomon, Scott D., additional, Steg, Philippe Gabriel, additional, Braunwald, Eugene, additional, McMurray, John J.V., additional, Pfeffer, Marc A., additional, and Køber, Lars, additional

Published
2023
Full Text
View/download PDF

10. Geographic Differences in Patients With Acute Myocardial Infarction in The PARADISE‐MI Trial

Author

Butt, Jawad H, primary, Claggett, Brian L, additional, Miao, Zi M, additional, Jering, Karola S, additional, Sim, David, additional, van der Meer, Peter, additional, Ntsekhe, Mpiko, additional, Amir, Offer, additional, Cho, Myeong‐Chan, additional, Carrillo‐Calvillo, Jorge, additional, Núñez, Julio E, additional, Cadena, Alberto, additional, Kerkar, Prafulla, additional, Maggioni, Aldo P, additional, Steg, Philippe G, additional, Granger, Christopher B, additional, Mann, Douglas L, additional, Merkely, Béla, additional, Lewis, Eldrin F, additional, Solomon, Scott D, additional, Zhou, Yinong, additional, Køber, Lars, additional, Braunwald, Eugene, additional, McMurray, John JV, additional, and Pfeffer, Marc A, additional

Published
2023
Full Text
View/download PDF

12. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial

Author

Berwanger, Otavio, primary, Pfeffer, Marc, additional, Claggett, Brian, additional, Jering, Karola S., additional, Maggioni, Aldo P., additional, Steg, Philippe Gabriel, additional, Mehran, Roxana, additional, Lewis, Eldrin F., additional, Zhou, Yinong, additional, van der Meer, Peter, additional, De Pasquale, Carmine, additional, Merkely, Béla, additional, Filippatos, Gerasimos, additional, McMurray, John J.V., additional, Granger, Christopher B., additional, Solomon, Scott D., additional, and Braunwald, Eugene, additional

Published
2022
Full Text
View/download PDF

13. Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence

Author

Bracun, Valentina, primary, van Essen, Bart, additional, Voors, Adriaan A., additional, van Veldhuisen, Dirk J., additional, Dickstein, Kenneth, additional, Zannad, Faiez, additional, Metra, Marco, additional, Anker, Stefan, additional, Samani, Nilesh J., additional, Ponikowski, Piotr, additional, Filippatos, Gerasimos, additional, Cleland, John G.F., additional, Lang, Chim C., additional, Ng, Leong L., additional, Shi, Canxia, additional, de Wit, Sanne, additional, Aboumsallem, Joseph Pierre, additional, Meijers, Wouter C., additional, Klip, IJsbrand T., additional, van der Meer, Peter, additional, and de Boer, Rudolf A., additional

Published
2022
Full Text
View/download PDF

14. Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry

Author

Tromp, Jasper, Beusekamp, Joost C., Ouwerkerk, Wouter, van der Meer, Peter, Cleland, John G. F., Angermann, Christiane E., Dahlström, Ulf, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Filippatos, Gerasimos, Dickstein, Kenneth, Collins, Sean P., Lam, Carolyn S. P., Tromp, Jasper, Beusekamp, Joost C., Ouwerkerk, Wouter, van der Meer, Peter, Cleland, John G. F., Angermann, Christiane E., Dahlström, Ulf, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Filippatos, Gerasimos, Dickstein, Kenneth, Collins, Sean P., and Lam, Carolyn S. P.

Abstract

Aims Few prior studies have investigated differences in precipitants leading to hospitalizations for acute heart failure (AHF) in a cohort with global representation. Methods and results We analysed the prevalence of precipitants and their association with outcomes in 18 553 patients hospitalized for AHF in REPORT-HF (prospective international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure) according to left ventricular ejection fraction subtype (reduced [HFrEF] and preserved ejection fraction [HFpEF]) and presentation (new-onset vs. decompensated chronic heart failure [DCHF]). Patients were enrolled from 358 centres in 44 countries stratified according to Latin America, North America, Western Europe, Eastern Europe, Eastern Mediterranean and Africa, Southeast Asia, and Western Pacific. Precipitants were pre-with mutually exclusive categories and selected according to the local investigators discretion. Outcomes included in-hospital and 1-year mortality. The median age was 67 (interquartile range 57-77) years, and 39% were women. Acute coronary syndrome (ACS) was the most common precipitant in patients with new-onset heart failure in all regions except for North America and Western Europe, where uncontrolled hypertension and arrhythmia, respectively, were the most common precipitants, independent of confounders. In patients with DCHF, non-adherence to diet/medication was the most common precipitant regardless of region. Uncontrolled hypertension was a more likely precipitant in HFpEF, non-adherence to diet/medication, and ACS were more likely precipitants in HFrEF. Patients admitted due to worsening renal function had the worst in-hospital (5%) and 1-year post-discharge (30%) mortality rates, regardless of region, heart failure subtype and admission type (p(interaction) >0.05 for all). Conclusion Data on global differences in precipitants for AHF highlight potential regional differences in targets for preventi

Published
2022
Full Text
View/download PDF

15. Water table depth modulates productivity and biomass across Amazonian forests

Author

Sousa, Thaiane R., primary, Schietti, Juliana, additional, Ribeiro, Igor O., additional, Emílio, Thaise, additional, Fernández, Rafael Herrera, additional, ter Steege, Hans, additional, Castilho, Carolina V., additional, Esquivel‐Muelbert, Adriane, additional, Baker, Timothy, additional, Pontes‐Lopes, Aline, additional, Silva, Camila V. J., additional, Silveira, Juliana M., additional, Derroire, Géraldine, additional, Castro, Wendeson, additional, Mendoza, Abel Monteagudo, additional, Ruschel, Ademir, additional, Prieto, Adriana, additional, Lima, Adriano José Nogueira, additional, Rudas, Agustín, additional, Araujo‐Murakami, Alejandro, additional, Gutierrez, Alexander Parada, additional, Andrade, Ana, additional, Roopsind, Anand, additional, Manzatto, Angelo Gilberto, additional, Di Fiore, Anthony, additional, Torres‐Lezama, Armando, additional, Dourdain, Aurélie, additional, Marimon, Beatriz, additional, Marimon, Ben Hur, additional, Burban, Benoit, additional, van Ulft, Bert, additional, Herault, Bruno, additional, Quesada, Carlos, additional, Mendoza, Casimiro, additional, Stahl, Clement, additional, Bonal, Damien, additional, Galbraith, David, additional, Neill, David, additional, de Oliveira, Edmar A., additional, Hase, Eduardo, additional, Jimenez‐Rojas, Eliana, additional, Vilanova, Emilio, additional, Arets, Eric, additional, Berenguer, Erika, additional, Alvarez‐Davila, Esteban, additional, Honorio Coronado, Eurídice N., additional, Almeida, Everton, additional, Coelho, Fernanda, additional, Valverde, Fernando Cornejo, additional, Elias, Fernando, additional, Brown, Foster, additional, Bongers, Frans, additional, Arevalo, Freddy Ramirez, additional, Lopez‐Gonzalez, Gabriela, additional, van der Heijden, Geertje, additional, Aymard C., Gerardo A., additional, Llampazo, Gerardo Flores, additional, Pardo, Guido, additional, Ramírez‐Angulo, Hirma, additional, do Amaral, Iêda Leão, additional, Vieira, Ima Célia Guimarães, additional, Huamantupa‐Chuquimaco, Isau, additional, Comiskey, James A., additional, Singh, James, additional, Espejo, Javier Silva, additional, del Aguila‐Pasquel, Jhon, additional, Zwerts, Joeri Alexander, additional, Talbot, Joey, additional, Terborgh, John, additional, Ferreira, Joice, additional, Barroso, Jorcely G., additional, Barlow, Jos, additional, Camargo, José Luís, additional, Stropp, Juliana, additional, Peacock, Julie, additional, Serrano, Julio, additional, Melgaço, Karina, additional, Ferreira, Leandro V., additional, Blanc, Lilian, additional, Poorter, Lourens, additional, Gamarra, Luis Valenzuela, additional, Aragão, Luiz, additional, Arroyo, Luzmila, additional, Silveira, Marcos, additional, Peñuela‐Mora, Maria Cristina, additional, Vargas, Mario Percy Núñez, additional, Toledo, Marisol, additional, Disney, Mat, additional, Réjou‐Méchain, Maxime, additional, Baisie, Michel, additional, Kalamandeen, Michelle, additional, Camacho, Nadir Pallqui, additional, Cardozo, Nállarett Dávila, additional, Silva, Natalino, additional, Pitman, Nigel, additional, Higuchi, Niro, additional, Banki, Olaf, additional, Loayza, Patricia Alvarez, additional, Graça, Paulo M. L. A., additional, Morandi, Paulo S., additional, van der Meer, Peter J., additional, van der Hout, Peter, additional, Naisso, Pétrus, additional, Camargo, Plínio Barbosa, additional, Salomão, Rafael, additional, Thomas, Raquel, additional, Boot, Rene, additional, Umetsu, Ricardo Keichi, additional, da Costa Silva, Richarlly, additional, Burnham, Robyn, additional, Zagt, Roderick, additional, Martinez, Rodolfo Vasquez, additional, Brienen, Roel, additional, Ribeiro, Sabina Cerruto, additional, Lewis, Simon L., additional, Vieira, Simone Aparecida, additional, de Almeida Reis, Simone Matias, additional, Fauset, Sophie, additional, Laurance, Susan, additional, Feldpausch, Ted, additional, Erwin, Terry, additional, Killeen, Timothy, additional, Wortel, Verginia, additional, Moscoso, Victor Chama, additional, Vos, Vincent, additional, Huasco, Walter Huaraca, additional, Laurance, William, additional, Malhi, Yadvinder, additional, Magnusson, William E., additional, Phillips, Oliver L., additional, and Costa, Flávia R. C., additional

Published
2022
Full Text
View/download PDF

16. Clinical implications of low estimated protein intake in patients with heart failure

Author

Streng, Koen W., primary, Hillege, Hans L., additional, ter Maaten, Jozine M., additional, van Veldhuisen, Dirk J., additional, Dickstein, Kenneth, additional, Ng, Leong L., additional, Samani, Nilesh J., additional, Metra, Marco, additional, Ponikowski, Piotr, additional, Cleland, John G., additional, Anker, Stefan D., additional, Romaine, Simon P.R., additional, Damman, Kevin, additional, van der Meer, Peter, additional, Lang, Chim C., additional, and Voors, Adriaan A., additional

Published
2022
Full Text
View/download PDF

17. Functional investigation of two simultaneous or separately segregating DSP variants within a single family supports the theory of a dose‐dependent disease severity

Author

Vermeer, Mathilde C. S. C., primary, Andrei, Daniela, additional, Kramer, Duco, additional, Nijenhuis, Albertine M., additional, Hoedemaekers, Yvonne M., additional, Westers, Helga, additional, Jongbloed, Jan D. H., additional, Pas, Hendri H., additional, van den Berg, Maarten P., additional, Silljé, Herman H. W., additional, van der Meer, Peter, additional, and Bolling, Maria C., additional

Published
2022
Full Text
View/download PDF

18. Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study

Author

Alnuwaysir, Ridha I.S., Grote Beverborg, Niels, Hoes, Martijn F., Markousis‐Mavrogenis, George, Gomez, Karla A., van der Wal, Haye H., Cleland, John G.F., Dickstein, Kenneth, Lang, Chim C., Ng, Leong L., Ponikowski, Piotr, Anker, Stefan D., van Veldhuisen, Dirk J., Voors, Adriaan A., and van der Meer, Peter

Abstract

Aims:\ud Whereas the combination of anaemia and chronic kidney disease (CKD) has been extensively studied in patients with heart failure (HF), the contribution of iron deficiency (ID) to this dysfunctional interplay is unknown. We aimed to assess clinical associates and pathophysiological pathways related to ID in this multimorbid syndrome.\ud \ud Methods and results:\ud We studied 2151 patients with HF from the BIOSTAT-CHF cohort. Patients were stratified based on ID (transferrin saturation

Published
2022

19. Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry

Author

Jackson, Alice M., Petrie, Mark C., Frogoudaki, Alexandra, Laroche, Cécile, Gustafsson, Finn, Ibrahim, Bassem, Mebazaa, Alexandre, Johnson, Mark R., Seferovic, Petar M., Regitz‐Zagrosek, Vera, Mbakwem, Amam, Böhm, Michael, Prameswari, Hawani Sasmaya, Abdel Gawad, Doaa Ahmed Fouad, Goland, Sorel, Damasceno, Albertino, Karaye, Kamilu, Farhan, Hasan Ali, Hamdan, Righab, Maggioni, Aldo P., Sliwa, Karen, Bauersachs, Johann, Meer, Peter, Favaloro, R., Favaloro, L., Carballo, M., Peradejordi, M., Renedo, M.F., Absi, D., Bertolotti, A., Ratto, R., Talavera, M.L., Gomez, R., Lockwood, S., Barton, T., Austin, M‐A., Arstall, M., Aldridge, E., Chow, Y.Y., Dekker, G., Mahadavan, G., Rose, J., Wittwer, M., Hoppe, U., Sandhofer, A., Bahshaliyev, A., Gasimov, Z., Babayev, A., Niftiyev, P., Hasanova, I., AlBannay, R., AlHaiki, W., Husain, A., Mahdi, N., Kurlianskaya, A., Lukyanchyk, M., Shatova, O., Troyanova‐Shchutskaia, T., Anghel, L., De Pauw, M., Gevaert, S., De Backer, J., De Hosson, M., Vervaet, P., Timmermans, P.J., Janssen, A., Yameogo, N.V., Kagambega, L.J., Cumyn, A., Caron, N., Cote, A‐M., Sauve, N., Nkulu, D. Ngoy, Lez, D. Malamba, Yolola, E. Ngoy, Krejci, J., Poloczkova, H., Ersboll, A., Gustafsson, F., Elrakshy, Y., Hassanein, M., Hammad, B., Eldin, O. Nour, Fouad, D., Salman, S., Zareh, Z., Abdeall, D., Elenin, H. Abo, Ebaid, H., El Nagar, A., Farag, S., Saed, M., El Rahman, Y H Abd, Ibrahim, B.S., Abdelhamid, M., Hanna, R.N. W., Youssef, G., Awad, R., Botrous, O.L. I., Halawa, S. Ibrahim, Nasr, G., Saad, A., El Tahlawi, M., Abdelbaset, M., El‐saadawy, M., El‐shorbagy, A., Shalaby, G., Anttonen, O., Tolppanen, H., Hamekoski, S., Menez, T., Noel, A., Lamblin, N., Mouquet, F., Coulon, C., Groote, P., Langlois, S., Schurtz, G., Cohen‐Solal, A., Mebazaa, A., Fournier, M‐C., Louadah, B., Akrout, N., Logeart, D., Leurent, G., Jovanova, S., Arnaudova‐Dezulovicj, F., Livrinova, V., Bauersachs, J., Hilfiker‐Kleiner, D., Berliner, D., Jungesblut, M., Koenig, T., Moulig, V.A., Pfeffer, T.J., Böhm, M., Kindermann, I., Schwarz, V., Schmitt, C., Swojanowsky, P., Pettit, S., Petrie, M., McAdam, M., Patton, D., Bakhai, A., Krishnamurthy, V., Lim, L., Clifford, P., Bowers, N., Clark, A. L., Witte, K., Cullington, D., Oliver, J., Simms, A., Mcginlay, M., McDonagh, T., Shah, A. M., Amin‐Youssef, G., De Courcey, J., Martin, K., Shaw, S., Vause, S., Wallace, S., Malin, G., Wick, C., Nikolaou, M., Rentoukas, I., Chinchilla, H., Andino, L., Iyengar, S., Chandra, S., Yadav, D.K., Babu, R. Ravi, Singh, A.K., Kumar, S., Karunamay, B.B., Chaubey, S.K., Dhiman, S.R., Jha, V.C., Singh, S.K., Kodati, D., Dasari, R., Sultana, S., Dewi, T.I., Prameswari, H. Sasmaya, Al‐Farhan, H.A., Al‐Hussein, A., Yaseen, I.F., Al‐Azzawi, Falah, Al‐Saedi, Ghazi, Mahmood, G.M., Mohammed, M.K., Ridha, A.F., Shotan, A., Vazan, A., Goland, S., Biener, M., Senni, M., Grosu, A., Martin, E., Esposti, D. Degli, Bacchelli, S., Borghi, C., Metra, M., Sciatti, E., Orabona, R., Sani, F., Brunetti, N.D., Sinagra, G., Bobbo, M., D'Agata Mottolese, B., Gesuete, V., Rakar, S., Ramani, F., Kamiya, C., Barasa, A., Ngunga, M., Bajraktari, G., Hyseni, V., Lleshi, D., Pllana, E., Pllana, T., Noruzbaeva, A., Ismailov, F., Mirrakhimov, E., Abilova, S., Lunegova, O., Kerimkulova, A., Osmankulova, G., Duishenalieva, M., Kurmanbekova, B., Turgunov, M., Mamasaidova, S., Bektasheva, E., Kavoliuniene, A., Muckiene, G., Vaitiekiene, A., Celutkiene, J., Balkevicine, L., Barysiene, J., Chee, K.H., Damasceno, A., Machava, M., Veldhuisen, D.J., Meer, P., Berg, M., Roos‐Hesselink, J., Hagen, I., Baris, L., Hurtado, P., Ezeonu, P., Isiguzo, G., Obeka, N., Onoh, R., Asogwa, F., Onyema, C., Otti, K., Ojji, D., Odili, A., Nwankwo, A., Karaye, K., Ishaq, N., Sanni, B., Abubakar, H., Mohammed, B., Sani, M., Kehinde, M., Mbakwem, A., Afolabi, B., Amadi, C., Kilasho, M., Qamar, N., Furnaz, S., Gurmani, S., Kayani, M.G.A. Mahmood, Munir, R., Hussain, S., Malik, S., Mumtaz, S., Saligan, J.R., Rubis, P., Biernacka‐Fijalkowska, B., Lesniak‐Sobelga, A., Wisniowska‐Smialek, S., Kasprzak, J.D., Lelonek, M., Zycinski, P., Jankowski, L., Grajek, S., Oko‐Sarnowska, Z., Rutkowska, A. Bartczak, Kaluzna‐Oleksy, M., Plaskota, K., Demkow, M., Dzielinska, Z., Henzel, J., Kryczka, K., Moiseeva, O., Irtyuga, O., Karelkina, E., Zazerskaya, I., Seferovic, P.M., Milinkovic, I., Živkovic, I., Ristic, A.D., Milasinovic, D., Kong, W. KF, Tan, L.K., Tan, J.L., Thain, S., Poh, K.K., Yip, J., Sliwa, K., Azibani, F., Hovelmann, J., Viljoen, C., Briton, O., Zamora, E., Orcajo, N. Alonso, Carbonell, R., Pascual, C., Muncharaz, J. Farre, Alonso‐Pulpon, L., Cubero, J. Segovia, Urquia, M. Taibo, Garcia‐Pavia, P., Gomez‐Bueno, M., Cobo‐Marcos, M., Briceno, A., Galvan, E. De Teresa, Garcia‐Pinilla, J.M., Robles‐Mezcua, A., Morcillo‐Hildalgo, L., Elbushi, A., Suliman, A., Ahamed, N., Jazzar, K., Murtada, M., Schaufelberger, M., Goloskokova, V., Hullin, R., Yarol, N., Arrigo, M., Cavusoglu, Y., Eraslan, S., Fak, A.S., Enar, S. Catirli, Sarac, L., Cankurtaran, B., Gumrukcuoglu, H., Ozturk, F., Omagino, J., Mondo, C., Lwabi, P., Ingabire, P., Nabbaale, J., Nyakoojo, W., Okello, E., Sebatta, E., Ssinabulya, I., Atukunda, E., Kitooleko, S., Semu, T., Salih, B.T., Komaranchath, A.M., Almahmeed, W.A.R., Gerges, F., Farook, F.S. Mohamed, Albakshy, F., Mahmood, N., Wani, S., Freudenberger, R., Islam, N., Quinones, J., Sundlof, D., Beitler, C., Centolanza, L., Cornell, K., Huffaker, S., Matos, L., Marzo, K., Paruchuri, V., Patel, D., Abdullaev, T., Alyavi, B., Mirzarakhimova, S., Tsoy, I., Bekbulatova, R., and Uzokov, J.

Abstract

Aims: \ud Hypertensive disorders occur in women with peripartum cardiomyopathy (PPCM). How often hypertensive disorders co-exist, and to what extent they impact outcomes, is less clear. We describe differences in phenotype and outcomes in women with PPCM with and without hypertensive disorders during pregnancy.\ud \ud Methods: \ud The European Society of Cardiology PPCM Registry enrolled women with PPCM from 2012-2018. Three groups were examined: 1) women without hypertension (‘PPCM-noHTN’); 2) women with hypertension but without pre-eclampsia (‘PPCM-HTN’); 3) women with pre-eclampsia (‘PPCM-PE’). Maternal (6-month) and neonatal outcomes were compared.\ud \ud Results: \ud Of 735 women included, 452 (61.5%) had PPCM-noHTN, 99 (13.5%) had PPCM-HTN and 184 (25.0%) had PPCM-PE. Compared to women with PPCM-noHTN, women with PPCM-PE had more severe symptoms (NYHA IV in 44.4% and 29.9%, p

Published
2021

20. Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT‐HF registry

Author

Tromp, Jasper, primary, Beusekamp, Joost C., additional, Ouwerkerk, Wouter, additional, van der Meer, Peter, additional, Cleland, John G.F., additional, Angermann, Christiane E., additional, Dahlstrom, Ulf, additional, Ertl, Georg, additional, Hassanein, Mahmoud, additional, Perrone, Sergio V., additional, Ghadanfar, Mathieu, additional, Schweizer, Anja, additional, Obergfell, Achim, additional, Filippatos, Gerasimos, additional, Dickstein, Kenneth, additional, Collins, Sean P, additional, and Lam, Carolyn S.P., additional

Published
2022
Full Text
View/download PDF

22. Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure ( PUSH‐AHF ) trial

Author

ter Maaten, Jozine M., primary, Beldhuis, Iris E., additional, van der Meer, Peter, additional, Krikken, Jan A., additional, Coster, Jenifer E., additional, Nieuwland, Wybe, additional, van Veldhuisen, Dirk J., additional, Voors, Adriaan A., additional, and Damman, Kevin, additional

Published
2022
Full Text
View/download PDF

24. Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from theBIOSTAT‐CHFstudy

Author

Alnuwaysir, Ridha I.S., primary, Grote Beverborg, Niels, additional, Hoes, Martijn F., additional, Markousis‐Mavrogenis, George, additional, Gomez, Karla A., additional, Wal, Haye H., additional, Cleland, John G.F., additional, Dickstein, Kenneth, additional, Lang, Chim C., additional, Ng, Leong L., additional, Ponikowski, Piotr, additional, Anker, Stefan D., additional, Veldhuisen, Dirk J., additional, Voors, Adriaan A., additional, and Meer, Peter, additional

Published
2021
Full Text
View/download PDF

25. Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

Author

Butler, Javed, primary, Anker, Stefan D., additional, Siddiqi, Tariq Jamal, additional, Coats, Andrew J.S., additional, Dorigotti, Fabio, additional, Filippatos, Gerasimos, additional, Friede, Tim, additional, Göhring, Udo‐Michael, additional, Kosiborod, Mikhail N., additional, Lund, Lars H., additional, Metra, Marco, additional, Moreno Quinn, Carol, additional, Piña, Ileana L., additional, Pinto, Fausto J., additional, Rossignol, Patrick, additional, Szecsödy, Peter, additional, Van Der Meer, Peter, additional, Weir, Matthew, additional, and Pitt, Bertram, additional

Published
2021
Full Text
View/download PDF

26. Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Author

Sliwa, Karen, Meer, Peter, Petrie, Mark C., Frogoudaki, Alexandra, Johnson, Mark R., Hilfiker‐Kleiner, Denise, Hamdan, Righab, Jackson, Alice M., Ibrahim, Bassem, Mbakwem, Amam, Tschöpe, Carsten, Regitz‐Zagrosek, Vera, Omerovic, Elmir, Roos‐Hesselink, Jolien, Gatzoulis, Michael, Tutarel, Oktay, Price, Susanna, Heymans, Stephane, Coats, Andrew JS, Müller, Christian, Chioncel, Ovidiu, Thum, Thomas, Boer, Rudolf A., Jankowska, Ewa, Ponikowski, Piotr, Lyon, Alexander R., Rosano, Guiseppe, Seferovic, Petar M., and Bauersachs, Johann

Abstract

This position paper focusses on the pathophysiology, diagnosis and management of women diagnosed with a cardiomyopathy, or at risk of heart failure (HF), who are planning to conceive or present with (de novo or previously unknown) HF during or after pregnancy. This includes the heterogeneous group of heart muscle diseases such as hypertrophic, dilated, arrhythmogenic right ventricular and non-classified cardiomyopathies, left ventricular non-compaction, peripartum cardiomyopathy, Takotsubo syndrome, adult congenital heart disease with HF, and patients with right HF. Also, patients with a history of chemo-/radiotherapy for cancer or haematological malignancies need specific pre-, during and post-pregnancy assessment and counselling. We summarize the current knowledge about pathophysiological mechanisms, including gene mutations, clinical presentation, diagnosis, and medical and device management, as well as risk stratification. Women with a known diagnosis of a cardiomyopathy will often require continuation of drug therapy, which has the potential to exert negative effects on the foetus. This position paper assists in balancing benefits and detrimental effects.

Published
2021

27. Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients

Author

Tkaczyszyn, Michał, primary, Comín‐Colet, Josep, additional, Voors, Adriaan A., additional, Veldhuisen, Dirk J., additional, Enjuanes, Cristina, additional, Moliner, Pedro, additional, Drozd, Marcin, additional, Sierpiński, Radosław, additional, Rozentryt, Piotr, additional, Nowak, Jolanta, additional, Suchocki, Tomasz, additional, Banasiak, Waldemar, additional, Ponikowski, Piotr, additional, Meer, Peter, additional, and Jankowska, Ewa A., additional

Published
2021
Full Text
View/download PDF

30. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics

Author

Jering, Karola S., primary, Claggett, Brian, additional, Pfeffer, Marc A., additional, Granger, Christopher, additional, Køber, Lars, additional, Lewis, Eldrin F., additional, Maggioni, Aldo P., additional, Mann, Douglas, additional, McMurray, John J.V., additional, Rouleau, Jean‐Lucien, additional, Solomon, Scott D., additional, Steg, Philippe G., additional, van der Meer, Peter, additional, Wernsing, Margaret, additional, Carter, Katherine, additional, Guo, Weinong, additional, Zhou, Yinong, additional, Lefkowitz, Martin, additional, Gong, Jianjian, additional, Wang, Yi, additional, Merkely, Bela, additional, Macin, Stella M., additional, Shah, Urmil, additional, Nicolau, Jose C., additional, and Braunwald, Eugene, additional

Published
2021
Full Text
View/download PDF

31. A network analysis to identify pathophysiological pathways distinguishing ischemic from non-ischemic heart failure

Author

Sama, Iziah E., Woolley, Rebecca J., Nauta, Jan F., Romaine, Simon P.R., Tromp, Jasper, ter Maaten, Jozine M., van der Meer, Peter, Lam, Carolyn S.P., Samani, Nilesh J., Ng, Leong L., Metra, Marco, Dickstein, Kenneth, Anker, Stefan D., Zannad, Faiez, Lang, Chim C., Cleland, John G.F., van Veldhuisen, Dirk J., Hillege, Hans L., and oors, Adriaan A.V.

Abstract

Aims\ud Heart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused by a primary disease of the myocardium (cardiomyopathy). In order to identify targeted therapies specific for either ischaemic or non‐ischaemic HF, it is important to better understand differences in underlying molecular mechanisms.\ud \ud Methods and results\ud We performed a biological physical protein–protein interaction network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic HF. First, differentially expressed plasma protein biomarkers were identified in 1160 patients enrolled in the BIOSTAT‐CHF study, 715 of whom had ischaemic HF and 445 had non‐ischaemic HF. Second, we constructed an enriched physical protein–protein interaction network, followed by a pathway over‐representation analysis. Finally, we identified key network proteins. Data were validated in an independent HF cohort comprised of 765 ischaemic and 100 non‐ischaemic HF patients. We found 21/92 proteins to be up‐regulated and 2/92 down‐regulated in ischaemic relative to non‐ischaemic HF patients. An enriched network of 18 proteins that were specific for ischaemic heart disease yielded six pathways, which are related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. We identified five key network proteins: acid phosphatase 5, epidermal growth factor receptor, insulin‐like growth factor binding protein‐1, plasminogen activator urokinase receptor, and secreted phosphoprotein 1. Similar results were observed in the independent validation cohort.\ud \ud Conclusions\ud Pathophysiological pathways distinguishing patients with ischaemic HF from those with non‐ischaemic HF were related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. The five key pathway proteins identified are potential treatment targets specifically for patients with ischaemic HF.

Published
2020

32. Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF

Author

Davison, Beth A., primary, Senger, Stefanie, additional, Sama, Iziah E., additional, Koch, Gary G., additional, Mebazaa, Alexandre, additional, Dickstein, Kenneth, additional, Samani, Nilesh J., additional, Metra, Marco, additional, Anker, Stefan D., additional, Cleland, John G., additional, Ng, Leong L., additional, Mordi, Ify R., additional, Zannad, Faiez, additional, Filippatos, Gerasimos S., additional, Hillege, Hans L., additional, Ponikowski, Piotr, additional, van Veldhuisen, Dirk J., additional, Lang, Chim C., additional, van der Meer, Peter, additional, Núñez, Julio, additional, Bayés‐Genís, Antoni, additional, Edwards, Christopher, additional, Voors, Adriaan A., additional, and Cotter, Gad, additional

Published
2021
Full Text
View/download PDF

34. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality

Author

Sierpinski, Radoslaw, primary, Josiak, Krystian, additional, Suchocki, Tomasz, additional, Wojtas‐Polc, Katarzyna, additional, Mazur, Grzegorz, additional, Butrym, Aleksandra, additional, Rozentryt, Piotr, additional, Meer, Peter, additional, Comin‐Colet, Josep, additional, Haehling, Stephan, additional, Kosmala, Wojciech, additional, Przewlocka‐Kosmala, Monika, additional, Banasiak, Waldemar, additional, Nowak, Jolanta, additional, Voors, Adriaan A., additional, Anker, Stefan D., additional, Cleland, John G.F., additional, Ponikowski, Piotr, additional, and Jankowska, Ewa A., additional

Published
2020
Full Text
View/download PDF

35. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Author

de Boer, Rudolf A., primary, Hulot, Jean‐Sébastien, additional, Tocchetti, Carlo Gabriele, additional, Aboumsallem, Joseph Pierre, additional, Ameri, Pietro, additional, Anker, Stefan D., additional, Bauersachs, Johann, additional, Bertero, Edoardo, additional, Coats, Andrew J.S., additional, Čelutkienė, Jelena, additional, Chioncel, Ovidiu, additional, Dodion, Pierre, additional, Eschenhagen, Thomas, additional, Farmakis, Dimitrios, additional, Bayes‐Genis, Antoni, additional, Jäger, Dirk, additional, Jankowska, Ewa A., additional, Kitsis, Richard N., additional, Konety, Suma H., additional, Larkin, James, additional, Lehmann, Lorenz, additional, Lenihan, Daniel J., additional, Maack, Christoph, additional, Moslehi, Javid J., additional, Müller, Oliver J., additional, Nowak‐Sliwinska, Patrycja, additional, Piepoli, Massimo Francesco, additional, Ponikowski, Piotr, additional, Pudil, Radek, additional, Rainer, Peter P., additional, Ruschitzka, Frank, additional, Sawyer, Douglas, additional, Seferovic, Petar M., additional, Suter, Thomas, additional, Thum, Thomas, additional, van der Meer, Peter, additional, Van Laake, Linda W., additional, von Haehling, Stephan, additional, Heymans, Stephane, additional, Lyon, Alexander R., additional, and Backs, Johannes, additional

Published
2020
Full Text
View/download PDF

39. Clinical importance of urinary sodium excretion in acute heart failure

Author

Damman, Kevin, primary, Ter Maaten, Jozine M., additional, Coster, Jenifer E., additional, Krikken, Jan A., additional, van Deursen, Vincent M., additional, Krijnen, Hidde K., additional, Hofman, Mischa, additional, Nieuwland, Wybe, additional, van Veldhuisen, Dirk J., additional, Voors, Adriaan A., additional, and van der Meer, Peter, additional

Published
2020
Full Text
View/download PDF

40. Long‐term survivors of early breast cancer treated with chemotherapy are characterized by a pro‐inflammatory biomarker profile compared to matched controls

Author

Tromp, Jasper, primary, Boerman, Liselotte M., additional, Sama, Iziah E., additional, Maass, Saskia W.M.C., additional, Maduro, John H., additional, Hummel, Yoran M., additional, Berger, Marjolein Y., additional, de Bock, Geertruida H., additional, Gietema, Jourik A., additional, Berendsen, Annette J., additional, and van der Meer, Peter, additional

Published
2020
Full Text
View/download PDF

41. Myocardial dysfunction in long‐term breast cancer survivors treated at ages 40–50 years

Author

Jacobse, Judy N., primary, Steggink, Lars C., additional, Sonke, Gabe S., additional, Schaapveld, Michael, additional, Hummel, Yoran M., additional, Steenbruggen, Tessa G., additional, Lefrandt, Joop D., additional, Nuver, Janine, additional, Crijns, Anne P.G., additional, Aleman, Berthe M.P., additional, Meer, Peter, additional, Gietema, Jourik A., additional, and Leeuwen, Flora E., additional

Published
2020
Full Text
View/download PDF

42. Genetic risk and atrial fibrillation in patients with heart failure

Author

Kloosterman, Mariëlle, primary, Santema, Bernadet T., additional, Roselli, Carolina, additional, Nelson, Christopher P., additional, Koekemoer, Andrea, additional, Romaine, Simon. P.R., additional, Van Gelder, Isabelle C., additional, Lam, Carolyn S.P., additional, Artola, Vicente A., additional, Lang, Chim C., additional, Ng, Leon L., additional, Metra, Marco, additional, Anker, Stefan, additional, Filippatos, Gerasimos, additional, Dickstein, Kenneth, additional, Ponikowski, Piotr, additional, van der Harst, Pim, additional, van der Meer, Peter, additional, van Veldhuisen, Dirk J., additional, Benjamin, Emelia J., additional, Voors, Adriaan A., additional, Samani, Nilesh J., additional, and Rienstra, Michiel, additional

Published
2020
Full Text
View/download PDF

43. Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN‐HF registry

Author

Beusekamp, Joost C., primary, Teng, Tiew‐Hwa Katherine, additional, Tay, Wan Ting, additional, Ouwerkerk, Wouter, additional, Richards, A. Mark, additional, Anand, Inder S., additional, Chopra, Vijay K., additional, Wander, Gurpreet S., additional, Meer, Peter, additional, Voors, Adriaan A., additional, Lam, Carolyn S.P., additional, and Tromp, Jasper, additional

Published
2019
Full Text
View/download PDF

44. Selenium and outcome in heart failure

Author

Bomer, Nils, primary, Grote Beverborg, Niels, additional, Hoes, Martijn F., additional, Streng, Koen W., additional, Vermeer, Mathilde, additional, Dokter, Martin M., additional, IJmker, Jan, additional, Anker, Stefan D., additional, Cleland, John G.F., additional, Hillege, Hans L., additional, Lang, Chim C., additional, Ng, Leong L., additional, Samani, Nilesh J., additional, Tromp, Jasper, additional, van Veldhuisen, Dirk J., additional, Touw, Daan J., additional, Voors, Adriaan A., additional, and van der Meer, Peter, additional

Published
2019
Full Text
View/download PDF

45. The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach

Author

Hoes, Martijn F., primary, Tromp, Jasper, additional, Ouwerkerk, Wouter, additional, Bomer, Nils, additional, Oberdorf‐Maass, Silke U., additional, Samani, Nilesh J., additional, Ng, Leong L., additional, Lang, Chim C., additional, Harst, Pim, additional, Hillege, Hans, additional, Anker, Stefan D., additional, Metra, Marco, additional, Veldhuisen, Dirk J., additional, Voors, Adriaan A., additional, and Meer, Peter, additional

Published
2019
Full Text
View/download PDF

46. Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure

Author

Ponikowski, Piotr, primary, Kirwan, Bridget‐Anne, additional, Anker, Stefan D., additional, Dorobantu, Maria, additional, Drozdz, Jarosław, additional, Fabien, Vincent, additional, Filippatos, Gerasimos, additional, Haboubi, Teba, additional, Keren, Andre, additional, Khintibidze, Irakli, additional, Kragten, Hans, additional, Martinez, Felipe A., additional, McDonagh, Theresa, additional, Metra, Marco, additional, Milicic, Davor, additional, Nicolau, José C., additional, Ohlsson, Marcus, additional, Parhomenko, Alexander, additional, Pascual‐Figal, Domingo A., additional, Ruschitzka, Frank, additional, Sim, David, additional, Skouri, Hadi, additional, Meer, Peter, additional, and Jankowska, Ewa A., additional

Published
2019
Full Text
View/download PDF

47. Long-term prognosis, subsequent pregnancy, contraception and overall management of\ud peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Author

Sliwa, Karen, Petrie, Mark C., Hilfiker-Kleiner, Denise, Mebazaa, Alexandre, Jackson, Alice, Johnson, Mark R., van der Meer, Peter, Mbakwem, Amam, and Bauersachs, Johann

Abstract

Peripartum cardiomyopathy is an idiopathic cardiomyopathy presenting with heart failure secondary to left ventricular systolic dysfunction towards the end of pregnancy or in the months following delivery, where no other cause for heart failure is identified. Outcome varies from full recovery to residual left ventricular systolic dysfunction and even death. Many women return to their physician to acquire information on their long‐term prognosis, to seek medical advice regarding contraception, or when planning a subsequent pregnancy. This position paper summarizes current evidence for long‐term outcome, risk stratification of further pregnancies and overall management. Based on the best available evidence, as well as the clinical experience of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy members, a consensus on pre‐ and postpartum management algorithms for women undergoing a subsequent pregnancy is presented.

Published
2018

48. Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction

Author

Beusekamp, Joost C., Tromp, Jasper, van der Wal, Haye H., Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, van der Harst, Pim, Hillege, Hans L., Lang, Chim C., Metra, Marco, Ng, Leong L., Ponikowski, Piotr, Samani, Nilesh J., van Veldhuisen, Dirk J., Zwinderman, Aeilko H., Rossignol, Patrick, Zannad, Faiez, Voors, Adriaan A., and van der Meer, Peter

Subjects
cardiovascular diseases
Abstract

Background:\ud Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejection fraction (HFrEF). Whether it affects the use of renin–angiotensin–aldosterone system inhibitors and thereby negatively impacts outcome is unknown. Therefore, we investigated the association between potassium and uptitration of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) and its association with outcome.\ud \ud Methods and results:\ud Out of 2516 patients from the BIOSTAT-CHF study, potassium levels were available in 1666 patients with HFrEF. These patients were sub-optimally treated with ACEi/ARB or beta-blockers and were anticipated and encouraged to be uptitrated. Potassium levels were available at inclusion and at 9 months. Outcome was a composite of all-cause mortality and heart failure hospitalization at 2 years. Patients' mean age was 67 ± 12 years and 77% were male. At baseline, median serum potassium was 4.3 (interquartile range 3.9–4.6) mEq/L. After 9 months, 401 (24.1%) patients were successfully uptitrated with ACEi/ARB. During this period, mean serum potassium increased by 0.16 ± 0.66 mEq/L (P 0.5 for all).\ud \ud Conclusion:\ud Higher potassium levels are an independent predictor of enduring lower dosages of ACEi/ARB. Higher potassium levels do not attenuate the beneficial effects of ACEi/ARB uptitration.

Published
2018

49. Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment

Author

Nauta, Jan F., primary, Hummel, Yoran M., additional, Tromp, Jasper, additional, Ouwerkerk, Wouter, additional, van der Meer, Peter, additional, Jin, Xuanyi, additional, Lam, Carolyn S.P., additional, Bax, Jeroen J., additional, Metra, Marco, additional, Samani, Nilesh J., additional, Ponikowski, Piotr, additional, Dickstein, Kenneth, additional, Anker, Stefan D., additional, Lang, Chim C., additional, Ng, Leong L., additional, Zannad, Faiez, additional, Filippatos, Gerasimos S., additional, van Veldhuisen, Dirk J., additional, van Melle, Joost P., additional, and Voors, Adriaan A., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results